This is a new application for an R01 grant: """"""""Estrogen use in protection from cognitive decline"""""""" designed to assess effects of estrogen replacement therapy among postmenopausal women at risk for cognitive decline. We have collected pilot data, which suggest that estrogen use among older persons at risk for Alzheimer's Disease may be protective of regional cerebral metabolism, as measured by position emission tomography with 18-fluorodeoxyglucose (FDG-PET). A total of 71 postmenopausal women ages 50-65, estrogen users, will be randomized to continue or discontinue use and will be followed up to two years for changes in cerebral metabolism and cognitive performance. Subjects will undergo FDG-PET scans and neuropsychological assessments, initially and at the end of the two-year follow-up period. These procedures will allow us to evaluate regional, especially parietal, temporal, and posterior cingulate, cerebral glucose metabolism along with cognitive performance in postmenopausal women at baseline and upon random continuation vs. discontinuation of estrogen replacement therapy. Subjects who to discontinue estrogen use are hypothesized to show more evidence of decline than those who continue do. This project will expand current knowledge of effects of estrogen, by : (1) determining whether estrogen use among postmenopausal women at risk for cognitive decline is protective of brain metabolism; (2) identifying early predictors for cognitive decline; and (3) developing guidelines for estrogen use in postmenopausal women.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG022008-02
Application #
6791442
Study Section
Special Emphasis Panel (ZRG1-BDCN-1 (01))
Program Officer
Wagster, Molly V
Project Start
2003-08-15
Project End
2008-07-31
Budget Start
2004-08-01
Budget End
2005-07-31
Support Year
2
Fiscal Year
2004
Total Cost
$447,214
Indirect Cost
Name
Stanford University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Wroolie, Tonita E; Kenna, Heather A; Williams, Katherine E et al. (2015) Cognitive Effects of Hormone Therapy Continuation or Discontinuation in a Sample of Women at Risk for Alzheimer Disease. Am J Geriatr Psychiatry 23:1117-26
Rasgon, Natalie L; Kenna, Heather A; Wroolie, Tonita E et al. (2014) Insulin resistance and medial prefrontal gyrus metabolism in women receiving hormone therapy. Psychiatry Res 223:28-36
Jacobs, Emily G; Epel, Elissa S; Lin, Jue et al. (2014) Relationship between leukocyte telomere length, telomerase activity, and hippocampal volume in early aging. JAMA Neurol 71:921-3
Rasgon, Natalie L; Geist, Cheri L; Kenna, Heather A et al. (2014) Prospective randomized trial to assess effects of continuing hormone therapy on cerebral function in postmenopausal women at risk for dementia. PLoS One 9:e89095
Jacobs, Emily G; Kroenke, Candyce; Lin, Jue et al. (2013) Accelerated cell aging in female APOE-?4 carriers: implications for hormone therapy use. PLoS One 8:e54713
Kenna, Heather; Hoeft, Fumiko; Kelley, Ryan et al. (2013) Fasting plasma insulin and the default mode network in women at risk for Alzheimer's disease. Neurobiol Aging 34:641-9
Wroolie, Tonita E; Kenna, Heather A; Williams, Katherine E et al. (2011) Differences in verbal memory performance in postmenopausal women receiving hormone therapy: 17?-estradiol versus conjugated equine estrogens. Am J Geriatr Psychiatry 19:792-802
Lin, Jue; Kroenke, Candyce H; Epel, Elissa et al. (2011) Greater endogenous estrogen exposure is associated with longer telomeres in postmenopausal women at risk for cognitive decline. Brain Res 1379:224-31
Rasgon, Natalie L; Kenna, Heather A; Wroolie, Tonita E et al. (2011) Insulin resistance and hippocampal volume in women at risk for Alzheimer's disease. Neurobiol Aging 32:1942-8
Silverman, Daniel H S; Geist, Cheri L; Kenna, Heather A et al. (2011) Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD. Psychoneuroendocrinology 36:502-13